Clinical Trial Update: A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment

View source ↗

Summary

This update reports the completion of a Korean post-marketing surveillance study evaluating Erbitux (cetuximab) in patients with metastatic colorectal cancer re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Colorectal Neoplasms | Status: COMPLETED